**CURRICULUM VITAE**

**Date of Revision:** 11/11/21

**Name:**  Louis Trevisan, M.D.

**License:**  CT: 031693

**DEA:** BT2859025/XT2859025

**Phone:** 203-258-1008

**Education:** 1972 B.A. The College of Wooster, Wooster, Ohio

1981 M.Ed. Lewis and Clark College, Portland, Oregon

1985 B.S. Portland State University, Portland, Oregon

1989 M.D. Oregon Health Sciences University School of Medicine, Portland Oregon

**Career/Academic Appointments:**

1989 Oregon Health Sciences University School of Medicine, Portland OR

1990 Resident in Psychiatry, VA Connecticut Healthcare System, West Haven, CT

1990-1993 Post-Doctoral Fellow in Psychiatry, Yale University, New Haven, CT

1991 Resident in Adult Psychiatry, Yale-New Haven Hospital, New Haven, CT

1991-1992 Resident in Mental Hygiene Clinic, VA Connecticut Healthcare System, West Haven, CT

1992-1993 Chief Resident in Substance Abuse, VA Connecticut Healthcare System, West Haven, CT

1993-1995 Medical Director, Substance Abuse Inpatient Treatment Program, VA Connecticut Healthcare System, West Haven, CT

1993-1999 Staff Psychiatrist, Griffin Hospital, Derby, CT

1994-2012 Assistant Clinical Professor of Psychiatry, Yale University School of Medicine, New Haven, CT

1995-1996 Medical Director, Substance Abuse Day Rehabilitation Treatment Research, VA Connecticut Healthcare System, West Haven, CT

1995-1997 Medical Director, Evening Chemical Dependency Partial Hospital, Griffin Hospital, Derby, CT

1996-1997 Medical Director Inpatient Substance Abuse, VA Connecticut Healthcare System, West Haven, CT

1996-2009 Medical Director, Detoxification Services, VA Connecticut Healthcare System, West Haven, CT

1996-2009 Assistant Director of Substance Abuse Firm, VA Connecticut Healthcare System, West Haven, CT

1999-2000 General and Addiction Psychiatry, Spectrum Psychiatric Group, P. C., Hamden, CT

2000-2012 Geriatric Psychiatrist/Nursing Home Consultation, Geriatric Psychiatry Associates, P.C., Darien, CT

2008-2009 Associate Program Director, Addiction Fellowship, Yale University School of Medicine, New Haven, CT

2009-2016 Associate Chief of Psychiatry, VA Connecticut Healthcare System, Clinical Director

2016-2018 Veteran’s Integrated Service Network (VISN) 1 Mental Health Service Line Director

2018-2019 Tele-Substance Use Disorder Lead: National Tele-Mental Health Center, VA Connecticut Healthcare System

2012-2014 Associate Clinical Professor of Psychiatry, Yale University School of Medicine

2014-present Associate Professor of Psychiatry, Yale University School of Medicine

2019-2020 SAMHSA: Director, Center for Substance abuse Treatment

2020-present VACHS Tele-mental Health, Newington MHC, HUD-VASH/MHICM range, Psychiatric Emergency Room Attending, VA Connecticut Healthcare System.

2020-present Bridges Healthcare, Milford, CT Mobile MATT VAN (OUD Medication Treatment Services)

2020-present YNHHS/Yale University Department of Psychiatry, Ketamine Infusion MD

**Board Certification:**

American Board of Psychiatry and Neurology, October 1995, recertified 2005, recertified 2015

American Board of Psychiatry and Neurology, Subspecialty Certification in Addiction Psychiatry, April 1997, recertified 2007, recertified 2016

American Board of Psychiatry and Neurology, Subspecialty Certification in Geriatric Psychiatry, November 1996, recertified 2006

**Professional Honors & Recognition:**

**University**

1993 The Dr. Henry P. and M. Page Durkee Laughlin Foundation Merit Award, Department of Psychiatry, Yale University School of Medicine

2012 Nancy C. A. Roeske Award for Excellence in Medical Student Teaching, Yale University School of Medicine, American Psychiatric Association

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:**

**International/National**

2016: Course: “Updates in Geriatric Psychiatry” American Psychiatric Association 169th Annual Meeting, Atlanta, GA, May 14-18, 2016

2015: Symposium: “Management of Inappropriate Sexual Behaviors in Dementia (ISBD) Using Multidisciplinary Teams in the Continuum of Care, Annual Meeting of the American Association of Geriatric Psychiatry, New Orleans, LA. March 27-30, 2015

Course: “Updates in Geriatric Psychiatry” American Psychiatric Association 168th Annual Meeting, Toronto, Canada, May 16-20, 2015

2014: Symposium: Goldmine or Minefield: Navigating the Spectrum of Sexual Feeling and Behaviors in Older Adults: “Passion and Sentiment: Issues with Consent in Senescence” American Psychiatric Association 167th Annual Meeting, New York, NY, May 3-7, 2014

Presentation: American Academy of Addiction Psychiatry: Addictions and Their Treatment Course. Presenter: Special Populations. American Academy of Addiction Psychiatry: 25th Annual Meeting & Symposium. Aventura, FL, Dec 5-7, 2014

2013: Invited Speaker Engagement: “Elderly Substance Abuse Lecture”, *Montana Geriatric Education Center Conference*. Missoula, MT, October 15, 2013

Invited Speaker Engagement:“Alcohol Detoxification: A Risk Stratification Approach” *65th Institute on Psychiatric Services*, Philadelphia, PA, October 15, 2013

Presentation: American Academy of Addiction Psychiatry: Addictions and Their Treatment Course. Presenter: Special Populations. *American Academy of Addiction Psychiatry*: 24th Annual Meeting & Symposium. Scottsdale, AZ, Dec 2013

2012: Symposium: “Pain Medication Abuse in Older Americans: Recognition, Assessment and evidence Based Treatment in the Clinical Setting”. Trevisan L, Kirwin P, Joksovic J, Petrakis I. *American Association of Geriatric Psychiatry*, Annual Meeting, Washington, DC, 2012

Presentation: American Academy of Addiction Psychiatry: Addictions and Their Treatment Course. Presenter: Special Populations. *American Academy of Addiction Psychiatry*: 23rd Annual Meeting & Symposium. Aventura, FL, Dec 2012

2011 Symposium: “Baby Boomers and Substance Abuse: Recognition, Assessment and Evidence-Based Treatment in the Clinical Setting”. Cleves-Bayon JC, Kirwin P, Trevisan L, Shelby B. *American Association of Geriatric Psychiatry;* 24th Annual Meeting, San Antonio, TX, 2011: 19(3): S11-12

Presentation: American Academy of Addiction Psychiatry: Addictions and Their Treatment Course. Presenter: Special Populations. *American Academy of Addiction Psychiatry*: 22nd Annual Meeting & Symposium. Scottsdale, AZ, Dec 2011

2010: Workshop: “Life Long Substance Abuse and Management of Comorbid Medical Illness”. Trevisan L, Correa P, Cleves-Bayon JC. *American Association of Geriatric Psychiatry*, 23rd Annual Meeting, Savannah, Georgia, March 2010.

Presentation: American Academy of Addiction Psychiatry: Addictions and Their Treatment Course. Presenter: Special Populations. *American Academy of Addiction Psychiatry*: 21st Annual Meeting & Symposium. Boca Raton, FL, Dec 2010

2009: Workshop: “Woodstock Generation: Recognition, Assessment and Evidence Based Treatment of Elderly Substance Abuse in the Clinical Setting”. Trevisan L, Khatkhate G, Barnas M. *American Association of Geriatric Psychiatry*, 22nd Annual Meeting, Honolulu, Hawaii March 2009.

Presentation: American Academy of Addiction Psychiatry: Addictions and Their Treatment Course. Presenter: Special Populations. *American Academy of Addiction Psychiatry*: 20th Annual Meeting & Symposium. Los Angeles, CA, Dec 2009

Workshop: “Woodstock Generation: Recognition, Assessment and Evidence Based Treatment of Elderly Substance Abuse in the Clinical Setting”. Trevisan L, Khatekhate G, Barnas M. *American Academy of Addiction Psychiatry*: 20th Annual Meeting & Symposium. Los Angeles, CA, Dec 2009.

2008: Presentation, “Geriatric Substance Abuse: A Culturally Diverse Approach to Recognition, Assessment and Evidence Based Treatment in the Clinical Setting”. *American Association of Geriatric Psychiatry*, 21st Annual Meeting, Orlando, FL March 2008

Presentation: “Behavioral & Psychological Symptoms of Dementia: An Update”. *American Psychiatric Association*, 161st Annual Meeting, Washington D.C., May 2008.

2007: Workshop: “Geriatric Substance Abuse: Recognition, Assessment and Treatment in the Clinical Setting “. Trevisan L, Balchand K, Benga I, Oyamade A, Acampora A. *American Academy of Addiction Psychiatry:* 18th Annual Meeting & Symposium. Coronado, CA, Dec 2007.

**Regional**

2013: Invited Speaker Engagement: “Elderly Substance Abuse Lecture”. Massachusetts Addiction Medicine Society; Waltham, MA Massachusetts Medical Society, June 22, 2013.

2002-2010: Invited Speaking Engagement: “Substance Abuse and the Forensic Population” to Master Level Nurse Specialist Program, Quinnipiac University

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale:**

**International/National**

2016: Arias A, Mota N, Trevisan L, Southwick S, Pietrzak R. Subtypes of Alcohol Dependence in Military Veterans: A Latent Class Analysis. *American Journal on Addictions*, 2016; 25(4):314

Fuehrlein B, Mota N, Kachadourian L, Arias A, Trevisan L, Krystal J, Southwick S, Pietrzak R. High Burden of Alcohol Use Disorders in the US Veteran Population: Results from the National Health and Resilience in Veterans Study. *American Journal on Addictions*, 2016; 25(4):314

2015: Arias A, Mota N, Trevisan L, Southwick S, Pietrzak R. Subtypes of Alcohol Dependence in Military Veterans: A Latent Class Analysis. *Alc Clin Exp Res* 2015; 39:12A, San Antonio, TX

2012: Joksovic P, Kirwi P, Trevisan L. Prescription Pain Medication Abuse in Elderly. *American Academy of Addiction Psychiatry*: 23rd Annual Meeting & Symposium. Aventura, FL, Dec 2012

2010 Petrakis I, Pittman B, Limoncelli D, Koretski J, Newcomb J, Ralevski E, Trevisan L, Krystal J. Subjective response to IV ethanol using the clamp in young healthy adults both with and without family history of alcoholism. *Alc Clin Exp Res* 2010; 34(6): 137A

Petrakis, I, Gelernter J, Yang B, Pittman B, Limoncelli D, Koretski J, Newcomb J, Trevisan L, Perrino A, Krystal J. More evidence that the risk to develop alcoholism is mediated by glutamate: Role of Fyn kinase in subjective response to ketamine and ethanol. *Alc Clin Exp Res* 2010; 34(6): 69A.

2009: Petrakis I, Ralevski E, Trevisan L, Pittman B, Gueorguieva R, D'Souza DC, Perry E, Limoncelli D, Krystal JH. Mecamylamine Treatment for Alcohol Dependence in Smokers and Non-Smokers. *American Journal on Addictions* 2009; 18(4):328-329

Barnas ME, Khatkhate GP, Trevisan LA. Baby Boomers and Substance Abuse: Epidemiology, Assessment and Evidence Based Treatment. *American Journal of Geriatric Psychiatry* 2009; 17(3); A23.

2008: Trevisan L, Petrakis IL, Pittman B, Gueorguieva R, D’Souza DC, Perry E, Limoncelli D, Krystal JH. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycineB site of NMDA glutamate receptors. *Alc Clin Exp Res* 2008; 31(6); 50A

Trevisan L, Friedman G, Whang P, Lugo R. Geriatric Substance Abuse: A Culturally Diverse Approach to Recognition, Assessment and Evidence Based Treatment in the Clinical Setting. *American Journal of Geriatric Psychiatry* 2008; 16(3); A33

2007: Perrino A, Acampora G, Ralevski E, Edgecombe J, Limoncelli D, Trevisan L, Krystal J, Petrakis I. Analgesic Properties of Ethanol. *Alc Clin Exp Res* 2007; 31(6); 203A

2005: Petrakis IL, Ralevski E, Limoncelli D, Balachandra K, Trevisan L, Krystal J. Barbiturate Responses in Individuals with a Family Vulnerability to Alcoholism. *Alc Clin Exp Res* 2005; 29(5); 97A (#537).

Petrakis IL, Ralevski E, Limoncelli D, Desai N, Krystal J, Rounsaville B, Trevisan L, VA VISN I MIRECC Study Group. Naltrexone and Antidepressants in patients with PTSD & Alcohol Dependence. Alc Clin Exp Res 2005; 29(5); 78A (#425).

2003: Mason GF, Petrakis I, de Graaf R, Appel M, Gueorguieva R, Ruff E, Coric V, Trevisan L, Rothman D, Krystal J. Smoking effects on cortical GABA levels in ethanol withdrawal. *American College of Neuropsychopharmacology*, 2003; p. 194

Krystal JH, Petrakis IL, D’Souza DC, Limoncelli D, Webb E, Trevisan L, Boutros N, Gueorguieva R, Charney D. Alterations in NMDA Receptor Antagonist Response Associated with Human Alcohol Dependence and Familial Risk for Alcohol Dependence. Behavioural Pharmacology 2003; 14; S6-S7

Krystal JH, Petrakis I, Limoncelli D, Webb E, Gueorgueva R, Trevisan L, Boutros NN, D'Souza DC. Impact of Family Alcohol Dependence History Upon NMDA Receptor Function in Recovering Alcohol Dependent Patients. *Alc Clin Exp Res* 2003; 27(5); 46A (#246)

Krystal JH, Petrakis I, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS. Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol Dependent Patients. *Alc Clin Exp Res* 2003; 27(5); 19A (#79)

Petrakis, I, Trevisan L, O'Malley S, Vuppalapati D, Hould J, Limoncelli D, Krystal J. Gelatin "shots", an Alternative Method of Alcohol Administration in the Laboratory. *Alc Clin Exp Res* 2003; 27(5); 157A (#908)

Petrakis, I, Rounsaville B, Trevisan L, Boutros N, O'Malley S, Vuppalapati D, Gonzalez-Haddad G, Keegan K, Krystal J. Detoxification and Initiation of Abstinence from Alcohol Comparing Gabapentin, Valproic Acid and Placebo Augmentation of Benzodiazepine Escape. *Alc Clin Exp Res* 2003; 27(5); 148A (#857)

2001: Petrakis IL, Limoncelli D, Trevisan L, Boutros N, Gelernter J, Krystal JH. Altered NMDA antagonist responses associated with the familial alcoholism vulnerability and ethanol dependence in humans: possible therapeutic implications. *Biol Psychiatry* 2001; 49:77S (#269)

2000: Petrakis IL, Trevisan L, O’Malley S, Gelernter J, Krystal JH, Boutros N. The NMDA Dysregulation in individuals with a Family Vulnerability to Alcoholism. *Scientific Abstracts from the 39th American College of Nueropsychopharmacology Annual Meeting*; San Juan, Puerto Rico, December 10-14, 2000 (abstract 21).

Petrakis, I, Trevisan L, Boutros N, O’Malley S, Gelernter J, Krystal J. NMDA dysregulation in individuals with a family vulnerability to alcoholism. *Alc Clin Exp Res* 2000; 24(5): 12A (#35).

1998: Krystal JH, Behar K, Abi-Dargham A, Petrakis I, Laruelle M, Trevisan L, D’Souza DC, Mason G, Krasnicki S, Seibyl JP, Baldwin R, Charney DS, Innis R, Rothman D. GABAergic and glutamatergic alterations in alcohol dependent patients. Scientific *Abstracts from the 37th Annual Meeting of the American College of Neuropsychopharmacology.* Las Croabas, PR, December 14-18, 1998; 22

Krystal J, D’Souza DC, Petrakis I, Abi-Saab D, Gil R, Trevisan L, Vegso S, Cassello K, Charney DS. Glutamate-dopamine interactions in healthy human subjects: implications for the euphoric effects of ethanol. *Alcoholism: Clin Exp Res* 1998; 22:94-A (#545)

Krystal J, Petrakis I, Krasnicki S, Trevisan L, Boutros N, D’Souza DC. Altered responses to agonists of the strychnine-insensitive glycine NMDA coagonist (SIGLY) site in recently detoxified alcoholics.  *Alcoholism: Clin Exp Res* 1998; 22:94-A (#544)

Krystal J, Petrakis I, D’Souza DC, Karper L, Bennett A, Abi-Dargham A, Morrissey K, Trevisan L, Cassello K, Charney DS. GABA agonist-MNDA antagonist interactions in healthy human subjects: implications for ethanol effects in humans. *Alcoholism: Clin Exp Res* 1998; 22:94A (#543)

Petrakis I, Trevisan L, Boutros N, Krasnicki S, McHugh-Strong C. Plasma hormone and monoamine metabolite levels as predictors of cue-induced craving and alcohol self-administration in alcohol dependent individuals. *Alcoholism: Clin Exp Res* 1998; 22:44A (#245).

Krystal JH, Petrakis IL, D’Souza DC, Trevisan L, Karper L, Cooney N, Charney DS. Altered responses to the NMDA antagonist, ketamine, in recently detoxified early onset alcoholics. *The Glutamate Cascade: Common Pathways of Central Nervous System Disease States, Program Book*. Bethesda, MD: NIH 1998; 59

1997: Petrakis IL, Heninger GR, Trevisan L, D’Souza DC, Krystal JH. CSF measures of monoamine metabolites and neural-immune activation in alcohol dependent subjects compared to healthy volunteers. *Alcoholism Clin Exp Res* 1997; 21(suppl): 77A (abstract #441)

Krystal JH, Petrakis IL, D’Souza DC, Trevisan L, Krasnicki S, Charney DS. Interactive cognitive and ethanol-like effects of intravenous glycine and oral D-cycloserine in healthy human subjects. *Alcoholism Clin Exp Res* 1997; 21(suppl): 38A (abstract #209)

Krystal JH, Petrakis IL, D’Souza DC, Trevisan LA, Krasnicki S, Charney DS. Interactive effects of high dose intravenous glycine and oral D-cycloserine in healthy human subjects.  *Biol Psychiatry* 1997; 41(S): 23S (abstract #74)

1995: Krystal JH, Petrakis IL, Trevisan LA, Webb EH, Cooney NL, Karper LP, Namenworth SN, Casal LD, D’Souza DC, Heninger GR, Charney DS. Clinical evidence implicating NMDA receptors in ethanol effects and alcoholism. *American College of Neuropsychopharmacology Abstracts of Posters and Panels 34th Annual Meetin*g. San Juan, PR, December 11-15, 1995, p.60

Petrakis IL, Randall PK, Webb EH, Cooney NL, Karper LP, Namenworth SN, Trevisan LA, Charney DS, Krystal JH. Ketamine has dose-related ethanol-like effects in alcoholics. *Soc Neurosci Abstr* 1995; 21: 498 (#206.4)

Krystal JH, Petrakis IL, Webb EH, Cooney NL, Karper LP, Namenworth SN, Trevisan LA, Charney DS. Blunted ketamine responses in alcoholics. *Soc Neurosci Abstr* 1995; 21:498 (#206.3)

Randall PK, Trevisan LA, Namenworth SN, Petrakis IL, Webb EH, Charney DS, Krystal JH. Nimodipine for human alcohol detoxification: a preliminary open-label evaluation. *Alcoholism: Clin Exp Res* 1995; 19:67A (#384)

Abi-Dargham A, Krystal JH, Webb EH, Zoghbi S, Laruelle M, Petrakis IL, Trevisan LA, Randall PK, Baldwin RM, Hoffer PB, Charney DS, Innis RB: SPECT imaging of benzodiazepine receptors in alcoholics and healthy controls. *Alcoholism: Clin Exp Res* 1995; 19:10A (#41)

Trevisan LA, Namenworth SN, Petrakis IL, Randall PK, Charney DS, Krystal JH: Cycloserine modulation of human ethanol intoxication: implications for NMDA receptor contributions to human ethanol intoxication. *Alcoholism: Clin Exp Res* 1995; 19:4A (#4)

Krystal JH, Webb EH, Petrakis IL, Cooney NL, Namenworth SN, Trevisan LA, Karper LP, Randall P, Heninger GR, Charney DS: Blunted NMDA Antagonist Responses in recently detoxified alcoholics. *Alcoholism: Clin Exp Res* 1995; 19:4A (#3)

Krystal JH, Webb EH, Petrakis IL, Cooney NL, Namenworth SN, Trevisan L, Randall P, Heninger GR: Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. NMDA Antagonist Responses in recently detoxified alcoholics. *Alcoholism: Clin Exp Res* 1995; 19:4A (#2)

Krystal JH, Webb EH, Petrakis IL, Cooney NL, Karper LP, Namenworth SN, Trevisan LA, Randall PK, Charney DS: Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. *Alcoholism: Clin Exp Res* 1995; 19:4A (#2)

1993: Petrakis IL, Webb EH, Cooney NL, Trevisan LA, Charney DS, Krystal JH. CSF monoamine predictors and pharmacologic modulation of cue-induced craving in alcoholics. *American College of Neuropsychopharmacology 32nd Annual Meeting Abstracts of Panels and Posters*. Honolulu, HI 1993; 233

Petrakis IL, Webb EH, Cooney NL, Trevisan LA, Kranzler H, Karper LP, Charney DS, Krystal JH: Cue-induced craving in alcoholics: CSF monoamine predictors and pharmacologic modulation. *Soc Neurosci Abstr* 1993; 19: #595

**Professional Service**

**Professional Service for Professional Organizations:**

***American Academy of Addiction Psychiatry (AAAP)***

2009- present Lecturer American Academy of Addiction Psychiatry Review Course: Addiction in the Older Population/Special Populations

2018 PCSS Providers Clinical Support System: Substance Use Disorders on Older People: Webinar Date: submitted.

System

**Bibliography:**

**Peer-Reviewed Original Research**

1. Trevisan L, Fitzgerald FW, Brose N, Gasic GP, Heinemann SF, Duman RS, Nestler E J. Chronic Ethanol Increases Levels of NMDAR1 Immunoreactivity in Rat Hippocampus. *Journal of Neurochemistry* 1994; 62 (4): 1635-8.
2. Krystal JH, Petrakis IL, Webb EH, Cooney NL, Karper LP, Namenworth SN, Stetson P, Trevisan LA, Charney DS. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. *Archives of General Psychiatry*, 1998; 55:354-360.
3. Petrakis IL, Trevisan L, D’Souza DC, Gil R, Krasnicki S, Webb E, Heninger G, Cooney N, Krystal JH. CSF monoamine metabolite and beta endrophin levels in recently detoxified alcoholics and healthy controls: predicition of alcohol cue-induced craving. *Alcoholism: Clinical and Experimental Research*, 1999; 23(8): 1336-1341.
4. Petrakis IL, Trevisan L, Boutros NN, Limoncelli D, Cooney NL, Krystal JH. The Effects of Tryptophan Depletion on Alcohol Cue-Induced Craving in Abstinent Alcoholic Patients. *Alcoholism: Clinical and Experimental Research*, 2001; 25(8): 1151-1155.
5. Petry NM, Petrakis IL, Trevisan L, Wiredu G, Boutros N, Martin B, Kosten TR. Contingency management interventions: From research to practice. *American Journal of Psychiatry,* 2001; 158(5) 694-702.
6. Petrakis IL, Buonopane A, O’Malley S, Cermik O, Trevisan L, Boutros NN, Limoncelli D, Krystal JH. The effect of tryptophan depletion on alcohol self-administration in non-treatment seeking alcoholic individuals *Alcoholism: Clinical and Experimental Research,* 2002; 26(7): 969-975.
7. Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS. Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol Dependent Patients. *Neuropsychopharmacology,* 2003; 28(11):2020-8.
8. Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, Gelertner J, Krystal JH. Altered NMDA Glutamate Receptor Antagonist Response in Individuals with a Family Vulnerability to Alcoholism. *The American Journal of Psychiatry*, 2004; 161(10):1776-82.
9. Trevisan L, Petrakis IL, Pittman B, Gueorguieva R, D’Souza DC, Perry E, Limoncelli D, Krystal JH. Absence of Significant Interactive Effects of High-Dose D-Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights into Ethanol Actions at the GlycineB Site of NMDA Glutamate Receptors. *Alcoholism: Clinical and Experimental Research*, 2008; 32(1):36-42.
10. Trevisan LA, Ralevski E, Keegan K, Oville A, Vuppalapati D, Gonzalez G, Limoncelli D, Petrakis IL. Alcohol Detoxification and Relapse Prevention Using Valproic Acid versus Gabapentin in Alcohol-dependent Patients. *Addictive Disorders & Their Treatment*, 2008; 7(3):119-28.
11. Krystal JH, Petrakis IL, Limoncelli D, Nappi SK, Trevisan L, Pittman B, D'Souza DC. Characterization of the Interactive Effects of Glycine and D-Cycloserine in Men: Further Evidence for Enhanced NMDA Receptor Function Associated with Human Alcohol Dependence. *Neuropsychopharmacology*. 2011;36(4):701-10. PMCID PMC2949533.
12. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorgeuieva R, Rounsaville B, Krystal JH. Noradrenergic vs. Serotonergic Antidepressant with/without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. *Neuropsychopharmacology*, 2012; 37:996-1004. PMID: 22089316.
13. Fuerhrlein BS, Mota N, Arias AJ, Trevisan LA, Kachadourian LK, Krystal JH, Southwick SM, Pietrzak RH. The burden of alcohol use disorders in U.S. Military veterans: results from the National Health and Resilience in Veterans Study. *Addiction*, 2016; epub PMID: 27061707.
14. Hassell, C., Wilkins, K. & Trevisan, L.A. Pharmacology of geriatric substance use disorders: considerations and future directions Curr Treat Options Psych (2017) 4: 102. <https://doi.org/10.1007/s40501-017-0107-z>
15. Fuerhrlein BS, Mota N, Arias AJ, Trevisan LA, Kachadourian LK, Krystal JH, Southwick SM, Pietrzak RH. Trajectories of alcohol consumption in U.S. military veterans: Results from the National Health and Resilience in Veterans Study, T*he American Journal on Addictions*. 2018 April 18.doi: 10.1111/ajad.12731.
16. Yarnell, S., Li, L., MacGrory, B., Trevisan, L., Kirwin, P. Substance Use Disorders in Later Life: A Review and Synthesis of the Literature of an Emerging Public Health Concern, *American Journal of Geriatric Psychiatry*, *American Journal of Geriatric Psychiatry* May, 2019.
17. Fuehrein, BS, Bhalla, I., Goldenberg,M., Trevisan, L., Wilkins, K. Simulate to Stimulate: Manikin Based Simulation in the Psychiatry Clerkship. Academic Psychiatry, September 2019.
18. Tsai, J., Snitkin, M., Trevisan, L., Kraus, S., Pietrzak, R. Administration and Policy in Mental Health and Mental Health Services Research, September 2019
19. Tobias WD, Grunschel B, Stevens A, Capurso N, Ralevski E, Barkil-Oteo A, Trevisan L. Transforming Systems of care through a novel resident-led approach to morbidity and mortality conferences. Academic Psychiatry. 2016 Dec;40(6):893-897. Epub Aug 19.
20. Joshi P, Duong, K, Trevisan, L, et al. Evaluation and Management of Alcohol Use Disorder Among Older Adults. Current Geriatric Reports. 2021 Jul 24: 1-9. doi: [10.1007/s13670-021-00359-5](https://dx.doi.org/10.1007%2Fs13670-021-00359-5) [Epub ahead of print]

**Chapters, Books, and Reviews**

1. Nestler E, Guitart X, Ortiz J, Trevisan L. Second messenger and protein phosphorylation mechanisms underlying possible genetic vulnerability to alcoholism. (Review) *Annals of the New York Academy of Sciences* 1994; 708: 108-18.
2. Krystal JH, Petrakis IL, Trevisan L, Epperson N. Clinical neuroscience studies of behaviors associated with alcohol consumption in alcoholism. *NIAAA Neuroscience and Behavioral Portfolio Review*. Bethesda, MD, 1998; 1-38.
3. Trevisan L, Boutros N, Petrakis IL, Krystal J. Complications of alcohol withdrawal: pathophysiological insights. *Alcohol Health and Research World*, 1998; 22(1): 61-66.
4. Krystal JH, Petrakis IL, Trevisan L, Epperson N. Clinical neuroscience studies of behaviors associated with alcohol consumption in alcoholism. National Institute of Alcohol Abuse and Alcoholism, Research Monograph-34: *Review of NIAAA’ s Neuroscience and Behavioral Research Portfolio* 2000; 357-396.
5. Krystal JH, Petrakis IL, D’Souza C, Mason G, Trevisan L. Alcohol and glutamate neurotransmission in humans. *Contemporary Clinical Neurosicience: Glutamate and Addiction*, Herman B (ed), Totowa, NY: Humana Press Inc: 2002;1-9.
6. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. NMDA glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. *Pharmacology & Therapeutics 99*, 2003; 79-94.
7. Krystal JH, Petrakis IL, Krupitsky E, Schütz C, Trevisan L, D’Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. *Ann NY Acad Sci*, 2003; 1003: 176-184.
8. Trevisan LA. Baby boomers and substance abuse: an emerging issue. *Psychiatric Times*, 2008, Vol 25(8):28-36.
9. Drew S, Wilkins K, Trevisan LA. Managing medication and alcohol misuse in older patients. *Current Psychiatry*, 2010, Vol 9, No. 2:21-41.
10. Barkil-Oteo A, Bailey M, Cole R, Delphin-Rittmon, Devine S, Jaobs SC, Steiner L.Trevisan L, Sernyak MJ. Chapter 18: Administrative best practices in public psychiatry. *Yale Textbook of Public Psychiatry*, Jacobs S and Steiner J (eds) Oxford University Press: New York, NY 2016;
11. Burgos-Chapman I, Trevisan L, Sevarino K. Chapter 5: Abuse of opioids and prescription medications. *Addiction in the Older Patient,* Sullivan M & Levin F (eds) Oxford University Press: New York, NY 2016
12. Tsai, Jack, Trevisan L, Huang M, Pietrzak RH. Addressing veteran homelessness to prevent veteran suicides. Psychiatric Services 69:7 2018
13. Ford C and Trevisan, L. Chapter 21: Somatic symptoms and related disorders. current diagnosis and treatment: Psychiatry, Third Edition. Ebert, Leckman & Petrakis (eds) McGraw Hill Education, Lange. 2019
14. Ford C and Trevisan, L. Chapter 22: Factitious disorders and malingering. current diagnosis and treatment: Psychiatry, Third Edition. Ebert, Leckman & Petrakis (eds) McGraw Hill Education, Lange. 2019
15. Yarnell, S., and Trevisan, L. Role of Alcohol in Dementia. Unpublished.